These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7190078)

  • 1. Preparation and metabolism of a cisplatin/serum protein complex.
    Cole WC; Wolf W
    Chem Biol Interact; 1980 May; 30(2):223-35. PubMed ID: 7190078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Imaging agent for single photon emission computed tomography.
    Sathekge M; Wagener J; Smith SV; Soni N; Marjanovic-Painter B; Zinn C; Van de Wiele C; D'Asseler Y; Perkins G; Zeevaart JR
    Nuklearmedizin; 2013 Dec; 52(6):222-7. PubMed ID: 24108524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro).
    Perera A; Jackson H; Sharma HL; McAuliffe CA; Fox BW
    Chem Biol Interact; 1992 Dec; 85(2-3):199-213. PubMed ID: 1493609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal toxicity studies of protein-bound platinum(cis).
    Cole WC; Wolf W
    Chem Biol Interact; 1981 Jun; 35(3):341-8. PubMed ID: 7194744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and biodistribution of [195mPt]cisplatin(CISSPECT®) in head and neck squamous cell carcinoma.
    de Roest RH; Stigter van Walsum M; van der Schilden K; Brakenhoff RH
    EJNMMI Res; 2024 Mar; 14(1):22. PubMed ID: 38424294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man.
    Smith HS; Taylor DM
    J Nucl Med; 1974 May; 15(5):349-51. PubMed ID: 4823268
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cis-dichlorodiammineplatinum(II).
    DeSimone PA; Yancey RS; Coupal JJ; Butts JD; Hoeschel JD
    Cancer Treat Rep; 1979 Jun; 63(6):951-60. PubMed ID: 466654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive estimation of bound and mobile platinum compounds in the kidney using a radiopharmacokinetic model.
    Brechner RR; D'Argenio DZ; Dahalan R; Wolf W
    J Pharm Sci; 1986 Sep; 75(9):873-7. PubMed ID: 3783454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
    Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
    J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body autoradiographic study of the distribution of 195mPt in healthy and tumor-bearing mice treated with labeled cisplatin.
    Bénard P; Desplanches G; Macquet JP; Simon J
    Cancer Treat Rep; 1983 May; 67(5):457-66. PubMed ID: 6406060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.
    Gullo JJ; Litterst CL; Maguire PJ; Sikic BI; Hoth DF; Woolley PV
    Cancer Chemother Pharmacol; 1980; 5(1):21-6. PubMed ID: 6161715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorbed doses to patients from 191Pt-, 193mPt- and 195mPt-cisplatin.
    Areberg J; Norrgren K; Mattsson S
    Appl Radiat Isot; 1999 Nov; 51(5):581-6. PubMed ID: 10464923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in plasma pharmacokinetics of cisplatin in tumor-bearing rats.
    Litterst CL; Magin R
    Cancer Chemother Pharmacol; 1988; 22(1):1-4. PubMed ID: 3396142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of cisplatin nephrotoxicity by sodium selenite. Lack of interaction at the pharmacokinetic level of both compounds.
    Vermeulen NP; Baldew GS; Los G; McVie JG; De Goeij JJ
    Drug Metab Dispos; 1993; 21(1):30-6. PubMed ID: 8095223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity.
    Daley-Yates PT; McBrien DC
    Biochem Pharmacol; 1985 May; 34(9):1423-8. PubMed ID: 4039567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of cisplatin and related platinum complexes in plasma ultrafiltrate and urine by high-performance liquid chromatography with on-line radioactivity detection.
    Baldew GS; Volkers KJ; De Goeij JJ; Vermeulen NP
    J Chromatogr; 1989 Jun; 491(1):163-74. PubMed ID: 2793971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of Pt in the urine and kidney of the cisplatin treated rat.
    Mason RW; Hogg SJ; Edwards IR
    Toxicology; 1986 Feb; 38(2):219-26. PubMed ID: 3945972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacokinetics of four platinum cytostatics in rats.
    Láznícková A; Filipová M; Láznícek M; Drobník J; Svoboda D; Kvĕtina J
    Neoplasma; 1987; 34(2):173-81. PubMed ID: 3600883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro.
    Morris TT; Ruan Y; Lewis VA; Narendran A; Gailer J
    Metallomics; 2014 Nov; 6(11):2034-41. PubMed ID: 25255207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding kinetics of tetrachloro-1,2-diaminocyclohexaneplatinum (IV) (tetraplatin) and cis-diamminedichloroplatinum (II) at 37 degrees C with human plasma proteins and with bovine serum albumin. Does aquation precede protein binding?
    LeRoy AF; Thompson WC
    J Natl Cancer Inst; 1989 Mar; 81(6):427-36. PubMed ID: 2918550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.